Rochester, NY (PRWEB) September 10, 2013
The CBCD urges the medical community to refrain from becoming overly excited by the initiation of phase one human trials in the development of a new herpes vaccine.
The new clinical trial is headed up by Dr. Ian Frazer, who developed and patented the basic technology behind the HPV vaccine against cervical cancer. The vaccine patent was sold to Australian medical company CSL, and later to Merck Pharmaceuticals according to an article published on October 22, 2007 in The Science Times (2).
The medical community should remember that the FDA admits on its website (3) that the HPV vaccine contains DNA fragments. Indeed, the HPV vaccine manufacturing process is not keeping these fragments out. While the FDA believes that foreign DNA fragments are safe, the CBCD believes otherwise.
In fact, The Center believes that the poor safety record of the HPV vaccine, and the large number of people who report side effects (some of them severe), is due to the fragments of foreign DNA contained in it. The CBCD suggests that these foreign DNA fragments could be the cause of the autoimmune conditions observed by Israeli scientists, as suggested by Dr. Hanan Polansky’s Microcompetition with Foreign DNA Theory.
In addition to the concerns raised by the CBCD, leading scientists and health officials from around the world, including Japan, Italy, and Israel are raising serious concerns regarding the safety of the HPV vaccine according to The Japan Times in an article published on June 15, 2013 (4), and an article published in the Israeli newspaper, Haaretz on September 3rd, 2013 (5).
Israeli authors of one recent study on Frazer’s HPV vaccine wrote that there is “evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition.” They further wrote that, “The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the unc
Copyright©2012 Vocus, Inc.
All rights reserved